SciELO - Scientific Electronic Library Online

 
vol.47 número1Eficacia del reúso en hemodiálisis con dializadores de bajo y alto flujoAnemia hemolítica como expresión inicial de recidiva tumoral de neoplasia de mama índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Medicina

versión impresa ISSN 0034-7523versión On-line ISSN 1561-302X

Resumen

GOMEZ PADRON, María Virginia; TORRES, Wilfredo; GOMEZ PADRACUTEN, Enrique Ivo  y  MERIDA ALVAREZ, Oyantay. Should the antiphospholipid syndrome be considered as a new cardiovascular risk factor. Rev cubana med [online]. 2008, vol.47, n.1. ISSN 0034-7523.

The antiphospholipid syndrome is a thrombophilic state due to the presence in blood of antibodies directed against the prothrombin-phospholipid complex or against clotting factors-phospholipids affecting the conversion of the first one into thrombin and the activation of the second. A review was made to know if the antiphospholipid syndrome should be considered as a new cardiovascular risk factor, to determine the mechanisms of production of thrombosis, the new diagnostic criteria of the syndrome, and to describe the affections it produces at the level of the coronary endothelium and of the valvular and mural endocardium. It was concluded that the antiphospholipid syndrome should be considered as a new cardiovascular risk factor, since the antiphospholipid antibodies are able to generate a risk for heart affections at the endocardium level and to cause insufficiencies, valvular stenoses and intracavitary mural thrombosis. The antiphospholipid antibodies at the level of the valvular and mural endocardium produce transformations that turn them into a triggering source of systemic and pulmonary emboli. These antibodies at the level of the coronary endothelium may induce acute coronary syndromes with elevation of ST and without it, as well as to occlude the revascularized bridges and intracoronary devices. The antiphospholipid antibodies at the level of the microcirculation endothelium may trigger microthrombosis or thrombosis of the middle and large pulmonary branches, and secondarily provoke pulmonary hypertension. They can also develop intracoronary atherosclerosis and help to trigger chronic ischemic heart disease.

Palabras clave : Antiphospholipid syndrome; antiphospholipid antibodies; coronary thrombosis; insufficiency and valvular stenosis.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons